Boston Scientific Corporation $BSX Stock Holdings Boosted by Schear Investment Advisers LLC

Schear Investment Advisers LLC lifted its position in Boston Scientific Corporation (NYSE:BSX) by 45.0% during the first quarter, Holdings Channel reports. The institutional investor owned 39,882 shares of the medical equipment provider’s stock after buying an additional 12,370 shares during the quarter. Schear Investment Advisers LLC’s holdings in Boston Scientific were worth $2,503,000 at the end of the most recent reporting period.

Other institutional investors have also modified their holdings of the company. FWL Investment Management LLC acquired a new position in shares of Boston Scientific in the 2nd quarter worth approximately $26,000. Swiss RE Ltd. bought a new stake in shares of Boston Scientific in the 4th quarter worth approximately $26,000. Garton & Associates Financial Advisors LLC acquired a new stake in Boston Scientific during the fourth quarter valued at approximately $26,000. Bangor Savings Bank boosted its holdings in Boston Scientific by 94.7% during the fourth quarter. Bangor Savings Bank now owns 292 shares of the medical equipment provider’s stock worth $28,000 after buying an additional 142 shares in the last quarter. Finally, Board of the Pension Protection Fund bought a new stake in Boston Scientific during the fourth quarter worth approximately $29,000. Institutional investors and hedge funds own 89.07% of the company’s stock.

Boston Scientific Stock Up 2.0%

NYSE:BSX traded up $0.90 during trading hours on Tuesday, hitting $45.50. 3,577,777 shares of the company’s stock traded hands, compared to its average volume of 18,157,537. The stock’s fifty day moving average price is $50.99 and its two-hundred day moving average price is $69.27. The firm has a market cap of $67.63 billion, a P/E ratio of 19.15, a P/E/G ratio of 0.86 and a beta of 0.58. The company has a debt-to-equity ratio of 0.42, a quick ratio of 1.22 and a current ratio of 1.90. Boston Scientific Corporation has a twelve month low of $42.25 and a twelve month high of $109.50.

Boston Scientific (NYSE:BSX) last announced its quarterly earnings data on Wednesday, April 22nd. The medical equipment provider reported $0.80 EPS for the quarter, topping analysts’ consensus estimates of $0.79 by $0.01. Boston Scientific had a return on equity of 19.17% and a net margin of 17.29%.The firm had revenue of $5.20 billion during the quarter, compared to analyst estimates of $5.19 billion. During the same period last year, the company posted $0.75 EPS. The business’s quarterly revenue was up 11.6% compared to the same quarter last year. Boston Scientific has set its Q2 2026 guidance at 0.820-0.840 EPS and its FY 2026 guidance at 3.340-3.410 EPS. On average, research analysts expect that Boston Scientific Corporation will post 3.36 earnings per share for the current fiscal year.

Boston Scientific declared that its Board of Directors has approved a share repurchase plan on Monday, May 18th that permits the company to repurchase $5.00 billion in outstanding shares. This repurchase authorization permits the medical equipment provider to reacquire up to 6.4% of its stock through open market purchases. Stock repurchase plans are usually a sign that the company’s board of directors believes its stock is undervalued.

Insider Buying and Selling

In related news, Director David C. Habiger bought 2,250 shares of the firm’s stock in a transaction on Wednesday, May 20th. The stock was bought at an average price of $55.92 per share, with a total value of $125,820.00. Following the purchase, the director directly owned 13,878 shares of the company’s stock, valued at approximately $776,057.76. This represents a 19.35% increase in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, Director Cheryl Pegus purchased 1,770 shares of the stock in a transaction dated Wednesday, May 20th. The shares were bought at an average price of $56.49 per share, for a total transaction of $99,987.30. Following the completion of the acquisition, the director owned 1,770 shares in the company, valued at $99,987.30. This represents a ? increase in their ownership of the stock. The SEC filing for this purchase provides additional information. Over the last three months, insiders purchased 9,800 shares of company stock worth $554,012. 0.34% of the stock is owned by company insiders.

Wall Street Analysts Forecast Growth

BSX has been the topic of several research reports. Weiss Ratings cut Boston Scientific from a “hold (c)” rating to a “hold (c-)” rating in a report on Wednesday, May 13th. Robert W. Baird set a $70.00 price objective on Boston Scientific in a research note on Thursday, May 28th. Raymond James Financial restated an “outperform” rating and issued a $88.00 target price (down from $97.00) on shares of Boston Scientific in a report on Monday, March 30th. The Goldman Sachs Group set a $71.00 target price on Boston Scientific in a report on Thursday, May 28th. Finally, Daiwa Securities Group lowered Boston Scientific from a “strong-buy” rating to a “hold” rating in a research report on Wednesday, April 29th. One investment analyst has rated the stock with a Strong Buy rating, twenty-three have issued a Buy rating, five have assigned a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average target price of $82.12.

Boston Scientific Profile

Boston Scientific Corporation (NYSE: BSX) is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.

Boston Scientific’s activities span product development, clinical research, regulatory affairs and commercial sales.